Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid
Abstract
Abstract Carlson LA, Hamsten A, Asplund A (King Gustaf V Research Institute and Department of Internal Medicine, Karolinska Institute and Karolinska Hospital, Stockholm, Sweden). Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. Thirty‐one consecutive unselected hyperlipidaemic patients were treated daily with 4 g of nicotinic acid for 6 weeks. The concentrations in serum of lipoprotein Lp(a), and the major lipoprotein classes, were determined before and after the treatment. Nicotinic acid significantly reduced the serum levels of Lp(a) in the whole patient group. Linear regression analysis showed a strong negative relationship between the percentage reduction of Lp(a) and the serum triglyceride level before treatment (r = −0.78), which implied that for patients with a serum triglyceride concentration above 7.5 mmol l−1 there was a rise of Lp(a). The average individual percentage decrease of the concentration of Lp(a) was calculated after the exclusion of four patients who had serum triglyceride levels above 10 mmol l−1. The decrease was 38% with a 95% confidence interval of 28–47%. The absolute decrease of Lp(a) was correlated with the pretreatment levels of Lp(a) (r = 0.91). Within the whole group of patients there was a linear relationship between the percentage decrease of Lp(a) and that of LDL cholesterol (r = 0.88). This latter strong relationship might be due to an inhibition of the synthesis of the protein common to the two lipoproteins, apolipoprotein B.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nicotinic acid monotherapy at 3.0 g/day decreases the triglyceride level by 26%.
“Nicotinic acid monotherapy (3.0 g/day) causes a decrease in the TG level by 26%688).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [688]
Cites
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,377 · see citing works
Lp(a) Lipoprotein as a Risk Factor for Myocardial Infarction
Rhoads, G. G. (1986) · JAMA · doi:10.1001/jama.1986.03380180102027 · Cited by 774 · see citing works
Lipoprotein Lp(a) and the risk for myocardial infarction
Kostner, G. M., Avogaro, P., Cazzolato, G., Marth, E., Bittolo-Bon, G., & Qunici, G. B. (1981) · Atherosclerosis · doi:10.1016/0021-9150(81)90103-9 · Cited by 687 · see citing works
Human plasma lipoprotein [a]. Structural properties.
Gaubatz, J. W., Heideman, C. L., Gotto, A. M., et al. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32663-2 · Cited by 454 · see citing works
Carlson, L. A., & Orö, L. (1962) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1962.tb07203.x · Cited by 434 · see citing works
Self-citationLevels of lipoprotein Lp(a) decline with neomycin and niacin treatment
Gürakar, A. R., Hoeg, J. M., Kostner, G. M., et al. (1985) · Atherosclerosis · doi:10.1016/0021-9150(85)90041-3 · Cited by 261 · see citing works
Lipoprotein Lp(a). A risk factor for myocardial infarction.
Höefler, G., Harnoncourt, F., Paschke, E., et al. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.4.398 · Cited by 242 · see citing works
Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B.
Guyton, J. R., Dahlén, G., Patsch, W., Kautz, J. A., & Gotto, A. M. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.3.265 · Cited by 238 · see citing works
Armstrong, V. W., Walli, A. K., & Seidel, D. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34257-7 · Cited by 224 · see citing works
Progress in Biochemical Pharmacology
Paoletti, R., & VEHTUA, R. (1967) · Anesthesiology · doi:10.1097/00000542-196701000-00099 · Cited by 215 · see citing works
Treatment of Hyperlipoproteinemia.
(1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-5-822_2 · Cited by 155 · see citing works
Albers, J. J., Cabana, V. G., Warnick, G. R., et al. (1975) · Metabolism · doi:10.1016/0026-0495(75)90098-0 · Cited by 151 · see citing works
Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a)
Vessby, B., Kostner, G. M., Lithell, H., & Thomis, J. A. (1982) · Atherosclerosis · doi:10.1016/0021-9150(82)90053-3 · Cited by 145 · see citing works
Carlson, L. A. (1982) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1982.tb00938.x · Cited by 114 · see citing works
Self-citationEFFECT OF A SINGLE DOSE OF NICOTINIC ACID ON PLASMA LIPIDS IN PATIENTS WITH HYPERLIPOPROTEINEMIA
Carlson, L. A., Orö, L., & Östman, J. (1968) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1968.tb10508.x · Cited by 96 · see citing works
Self-citationFenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.
Shepherd, J., CASLAKE, M. J., Lorimer, A. R., Vallance, B. D., & Packard, C. J. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.2.162 · Cited by 96 · see citing works
Carlson, L. A., OLSSON, A. G., & Ballantyne, D. (1977) · Atherosclerosis · doi:10.1016/0021-9150(77)90127-7 · Cited by 93 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813 · see citing works
Khera, A. V., Everett, B. M., Caulfield, M. P., Hantash, F. M., Wohlgemuth, J., Ridker, P. M., & Mora, S. (2014) · Circulation · doi:10.1161/circulationaha.113.004406 · Cited by 461 · see citing works
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439 · see citing works
Lipoprotein metabolism and lipid management in chronic kidney disease
Kwan, B. C. H., Kronenberg, F., Beddhu, S., & Cheung, A. K. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006091006 · Cited by 354 · see citing works
Extreme lipoprotein(a) levels and improved cardiovascular risk prediction
Kamstrup, P. R., Tybjærg-Hansen, A., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.023 · Cited by 284 · see citing works
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover
Seed, M., O'Connor, B., Perombelon, N., O'Donnell, M., Reaveley, D., & Knight, B. L. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90102-z · Cited by 97 · see citing works
Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63 · see citing works
“At high doses, niacin also lowers Lp(a) by ≈30%.(49) As monotherapy, niacin administered to hypercholesterolemic men reduced the risk of recurrent myocardial infarction in the Coronary Drug Project(50) and also reduced total mortality in a 15-year follow-up.”
BackgroundMatsunaga, A., Handa, K., Mori, T., Moriyama, K., Hidaka, K., Yuki, M., Sasaki, J., & Arakawa, K. (1992) · Atherosclerosis · doi:10.1016/0021-9150(92)90249-g · Cited by 23 · see citing works
Enigmatic role of lipoprotein(a) in cardiovascular disease.
Anuurad, E., Enkhmaa, B., & Berglund, L. (2010) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2010.00238.x · Cited by 14 · see citing works
Dose-dependent effect of niceritrol on plasma lipoprotein-a
Teramoto, T., Yamada, N., Shimano, H., Oka, Y., Itakura, H., Saito, Y., Morisaki, N., Shirai, K., Ishikawa, T., Tada, N., et al. (1996) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519609090588 · Cited by 13 · see citing works
- Authors
- CARLSON, L. A., HAMSTEN, A., & ASPLUND, A.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- CARLSON, L. A.
- Venue
- Journal of Internal Medicine
- Publisher
- Wiley
- Published
- 1989-10
- Volume
- 226
- Issue
- 4
- Pages
- 271-276
- ISSN
- 0954-6820 (ISSN-L)
- 1365-2796
- OpenAlex
- W2004838889
- Cited by
- 443
- References
- 17
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 6 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 13 · 2014: 6 · 2013: 17 · 2012: 10
- FWCI
- 23.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), nicotinic acid, hyperlipidemia, serum triglycerides, LDL cholesterol, apolipoprotein B, lipid-lowering therapy
- MeSH terms
- Adult, Aged, Female, Humans, Hyperlipidemias, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Male, Middle Aged, Nicotinic Acids, Lipoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
